OPPOSING MITOGENIC REGULATION BY PACAP IN SYMPATHETIC AND CEREBRAL CORTICAL PRECURSORS CORRELATES WITH DIFFERENTIAL EXPRESSION OF PACAP RECEPTOR (PAC(1)-R) ISOFORMS
Nr. Lu et al., OPPOSING MITOGENIC REGULATION BY PACAP IN SYMPATHETIC AND CEREBRAL CORTICAL PRECURSORS CORRELATES WITH DIFFERENTIAL EXPRESSION OF PACAP RECEPTOR (PAC(1)-R) ISOFORMS, Journal of neuroscience research, 53(6), 1998, pp. 651-662
Neurogenesis in the peripheral and central nervous systems proceeds in
region-specific fashion, although underlying mechanisms remain undefi
ned. Emerging evidence indicates that the neuropeptide PACAP and its G
-protein-coupled receptor are expressed widely in the embryonic brain,
suggesting that the ligand/receptor system plays a role in developmen
t. We found previously that PAC(1)-R activation elicited opposing mito
genic effects in neurogenetic cultures, stimulating peripheral sympath
etic neuroblasts while inhibiting cerebral cortical precursors, We hav
e now defined the expression of PAC(1)-R mRNA isoforms and activation
of second-messenger pathways in these model populations, Sympathetic n
euroblasts express the ''hop'' receptor isoform, through which PACAP e
licits increased levels of cAMP and activation of the PI signaling pat
hway. In contrast, cerebral cortical precursors express primarily the
''short'' (non-insert) receptor isoform and exhibit increased cAMP lev
els alone following PACAP treatment. Thus, opposing mitogenic regulati
on in sympathetic and cortical precursors correlates with differential
receptor isoform expression and distinct second-messenger signaling.
In addition to receptor, PACAP ligand mRNA was expressed by both popul
ations, suggesting that the peptide is produced and acts locally to re
gulate precursor proliferation, These observations indicate that the P
ACAP ligand/receptor system is expressed in both the peripheral and ce
ntral nervous system during development. More generally, these studies
suggest that widely expressed extracellular factors mediate region-sp
ecific neurogenesis by activating lineage-restricted receptor isoforms
and intracellular pathways, (C) 1998 Wiley-Liss, Inc.